Skip To Content

Study ID: Boehringer Ingelheim BI1245.110 Emperor Heart Failure Trial

Title:

A phase III randomized, double blind trial to evaluate efficacy and safety of once daily empagliflozin 10mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction.

Location:
Sioux Falls Region
Principal Investigator:
Orvar Jonsson, MD
Disease:
Heart
Stage:
Unknown
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.